• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

腹水 HE4 水平可评估卵巢癌的化疗效果。

HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect.

机构信息

Department of Pathology, Harbin Medical University, 157 Baojian Road, Nangang District, Harbin, China.

Department of Oncologic Gynecology, Harbin Medical University Cancer Hospital, Harbin, China.

出版信息

J Ovarian Res. 2018 Jun 14;11(1):47. doi: 10.1186/s13048-018-0402-3.

DOI:10.1186/s13048-018-0402-3
PMID:29903044
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6002981/
Abstract

BACKGROUND

The clinical treatment of ovarian cancer with ascites is problematic. The main reasons for treatment failure are the susceptibility to intraperitoneal metastasis and chemotherapeutic drug resistance. The purpose and significance of this study is to evaluate which marker might evaluate treatment efficacy and improve the cure rate.

RESULTS

This study compared a no chemotherapy group with a chemotherapy group regarding the determination of carbohydrate antigen 125 and human epididymis protein 4 in ovarian cancer ascitic supernatants and cross-analyzed routine serum carbohydrate antigen 125 levels. The level of human epididymis protein 4 in the ascites of the chemotherapy group was significantly lower than that of the no chemotherapy group (p < 0.001). Moreover, the expression of ascitic human epididymis protein 4 correlated positively with serum carbohydrate antigen 125 levels (p < 0.001). MDR was positive in 13 of the 30 samples (43.33%) in the chemotherapy group with highly expressed CA125.

CONCLUSION

The level of human epididymis protein 4 in ovarian cancer ascites may reflect the therapeutic effect of ovarian cancer patients, and a high level of human epididymis protein 4 might predict chemoresistance and the possibility of ascites formation. The determination of the expression of human epididymis protein 4 alone or combined with carbohydrate antigen 125 levels in both serum and ascites in ovarian cancer patients with ascites may have important significance for guiding and improving the treatment regimen.

摘要

背景

卵巢癌合并腹水的临床治疗存在问题。治疗失败的主要原因是易发生腹腔内转移和化疗药物耐药。本研究的目的和意义在于评估哪种标志物可能评估治疗效果，提高治愈率。

结果

本研究比较了卵巢癌腹水上清液中糖链抗原 125 和人附睾蛋白 4 的测定值，对无化疗组和化疗组进行了分析，并对常规血清糖链抗原 125 水平进行了交叉分析。化疗组的人附睾蛋白 4 水平明显低于无化疗组（p<0.001）。此外，腹水人附睾蛋白 4 的表达与血清糖链抗原 125 水平呈正相关（p<0.001）。在化疗组的 30 个样本中（43.33%），有 13 个样本 MDR 呈阳性，CA125 高表达。

结论

卵巢癌腹水中人附睾蛋白 4 的水平可能反映卵巢癌患者的治疗效果，高水平的人附睾蛋白 4可能预测化疗耐药和腹水形成的可能性。单独或联合检测血清和腹水中人附睾蛋白 4 的表达水平，对指导和改善卵巢癌腹水患者的治疗方案可能具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b38d/6002981/89261249ce1f/13048_2018_402_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b38d/6002981/2c91c0da723c/13048_2018_402_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b38d/6002981/f413e9c0c93d/13048_2018_402_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b38d/6002981/9b81521f8d05/13048_2018_402_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b38d/6002981/89261249ce1f/13048_2018_402_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b38d/6002981/2c91c0da723c/13048_2018_402_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b38d/6002981/f413e9c0c93d/13048_2018_402_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b38d/6002981/9b81521f8d05/13048_2018_402_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b38d/6002981/89261249ce1f/13048_2018_402_Fig4_HTML.jpg

相似文献

1
HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect.腹水 HE4 水平可评估卵巢癌的化疗效果。
J Ovarian Res. 2018 Jun 14;11(1):47. doi: 10.1186/s13048-018-0402-3.
2
Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.血清人附睾蛋白4在预测上皮性卵巢癌手术预后较差方面优于癌抗原125。
Tumour Biol. 2016 Nov;37(11):14765-14772. doi: 10.1007/s13277-016-5335-0. Epub 2016 Sep 15.
3
Combined detection of sialic acid and hydroxyproline in diagnosis of ovarian cancer and its comparison with human epididymis protein 4 and carbohydrate antigen 125.联合检测唾液酸和羟脯氨酸在卵巢癌诊断中的应用及其与人附睾蛋白 4 和糖类抗原 125 的比较。
Clin Chim Acta. 2015 Jan 15;439:148-53. doi: 10.1016/j.cca.2014.10.026. Epub 2014 Oct 27.
4
Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.术前 ROMA 评分与上皮性卵巢癌患者临床分期的相关性。
Clin Transl Oncol. 2017 Oct;19(10):1260-1267. doi: 10.1007/s12094-017-1664-8. Epub 2017 Apr 25.
5
Approaches to the detection of ovarian cancer.卵巢癌的检测方法。
Scand J Clin Lab Invest Suppl. 2016;245:S49-53. doi: 10.1080/00365513.2016.1208452. Epub 2016 Jul 19.
6
The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.两种人附睾蛋白 4（HE4）检测系统联合 CA125 在卵巢肿块鉴别诊断中的诊断准确性。
Clin Chem Lab Med. 2011 Sep 16;49(12):2081-8. doi: 10.1515/CCLM.2011.709.
7
Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.卵巢癌患者腹水通过 Akt 依赖性途径刺激人腹膜间皮细胞中 MUC16 粘蛋白的表达和分泌。
BMC Cancer. 2019 Apr 30;19(1):406. doi: 10.1186/s12885-019-5611-7.
8
[Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].人附睾蛋白4与CA125联合检测在卵巢恶性肿瘤患者中的诊断价值
Zhonghua Zhong Liu Za Zhi. 2011 Jul;33(7):540-3.
9
[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].[血清人附睾分泌蛋白4及CA125检测在卵巢恶性肿瘤诊断中的价值]
Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6.
10
Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?评估 HE4 作为 CA125 的额外生物标志物以提高卵巢癌的检测：是否是向前迈进的一步？
Arch Gynecol Obstet. 2013 Jul;288(1):167-72. doi: 10.1007/s00404-013-2722-2. Epub 2013 Jan 30.

引用本文的文献

1
High-Density Gold Nanoparticles Implanted on Mg/Fe LDH Nanoflowers Assisted Lateral Flow Immuno-Dipstick Assay for Visual Detection of Human Epididymal Protein 4.高密度金纳米粒子植入 Mg/Fe LDH 纳米花辅助侧向流免疫层析法用于人附睾蛋白 4 的可视化检测
Biosensors (Basel). 2022 Sep 27;12(10):797. doi: 10.3390/bios12100797.
2
Human Epididymis Protein 4 and Lewis y Enhance Chemotherapeutic Resistance in Epithelial Ovarian Cancer Through the p38 MAPK Pathway.人附睾蛋白 4 和 Lewis y 通过 p38 MAPK 通路增强上皮性卵巢癌的化疗耐药性。
Adv Ther. 2022 Jan;39(1):360-378. doi: 10.1007/s12325-021-01941-1. Epub 2021 Nov 5.
3

本文引用的文献

1
Increased autophagy in EOC re-ascites cells can inhibit cell death and promote drug resistance.EOC 复发性腹水细胞中的自噬增加可抑制细胞死亡并促进耐药性。
Cell Death Dis. 2018 Apr 1;9(4):419. doi: 10.1038/s41419-018-0449-5.
2
The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.人附睾蛋白4在预测上皮性卵巢癌患者复发中的作用——来自OVCAD研究的结果。
Tumour Biol. 2016 Mar;37(3):3009-16. doi: 10.1007/s13277-015-4031-9. Epub 2015 Sep 29.
3
Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.
Detection of carcinoma in serous effusions: a review.
浆液性积液中癌的检测：综述
Am J Cancer Res. 2021 Jan 1;11(1):43-60. eCollection 2021.
4
CA125, CEA, CA19-9, and Heteroploid Cells in Ascites Fluid May Help Diagnose Peritoneal Carcinomatosis in Patients with Gastrointestinal and Ovarian Malignancies.腹水液中的CA125、癌胚抗原（CEA）、CA19-9及异倍体细胞可能有助于诊断胃肠道和卵巢恶性肿瘤患者的腹膜癌转移。
Cancer Manag Res. 2020 Oct 22;12:10479-10489. doi: 10.2147/CMAR.S271596. eCollection 2020.
腹水增加卵巢癌细胞中多药耐药蛋白的表达/功能。
PLoS One. 2015 Jul 6;10(7):e0131579. doi: 10.1371/journal.pone.0131579. eCollection 2015.
4
Value of detection of serum human epididymis secretory protein 4 and carbohydrate antigen 125 in diagnosis of early endometrial cancer of different pathological subtypes.血清人附睾分泌蛋白4和糖类抗原125检测在不同病理亚型早期子宫内膜癌诊断中的价值
Onco Targets Ther. 2015 May 26;8:1239-43. doi: 10.2147/OTT.S81853. eCollection 2015.
5
Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer.Lewis y和CAM-DR相关标志物的膜表达是上皮性卵巢癌化疗耐药和预后不良的独立因素。
Am J Cancer Res. 2015 Jan 15;5(2):830-43. eCollection 2015.
6
M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.M-CSF与HE4和CA 125组成的新型生物标志物组合用于上皮性卵巢癌患者的诊断。
J Ovarian Res. 2015 May 3;8:27. doi: 10.1186/s13048-015-0153-3.
7
Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.人附睾蛋白4在胰腺腺癌中的表达及诊断价值
Int J Mol Sci. 2015 Jan 29;16(2):2956-70. doi: 10.3390/ijms16022956.
8
Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.评估人附睾蛋白4（HE4）和卵巢恶性肿瘤风险算法（ROMA）作为日本女性I型和II型上皮性卵巢癌诊断工具的价值。
Tumour Biol. 2015 Feb;36(2):1045-53. doi: 10.1007/s13277-014-2738-7. Epub 2014 Oct 19.
9
Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.血清人附睾蛋白4（HE4）和癌抗原125（CA125）作为晚期高级别浆液性卵巢癌新辅助化疗疗效和预后的预测指标。
Tumour Biol. 2014 Dec;35(12):12389-95. doi: 10.1007/s13277-014-2553-1. Epub 2014 Sep 5.
10
Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.血清人附睾蛋白4与糖类抗原125作为卵巢癌标志物的比较：一项荟萃分析。
Mol Clin Oncol. 2014 Jul;2(4):559-566. doi: 10.3892/mco.2014.279. Epub 2014 Apr 16.